Search Medical Condition
Please enter condition
Please choose location from dropdown

Vallejo, California Clinical Trials

A listing of Vallejo, California clinical trials actively recruiting patient volunteers.

RESULTS

Found (92) clinical trials

Psoriasis Longitudinal Assessment and Registry (PSOLAR)

PSOLAR is an 8 year registry study. A registry is an observational study that evaluates the status of a disease. This registry study will only include patients who volunteer to take part. About 4000 infliximab-exposed patients, 4000 ustekinumab-exposed patients and as well as a comparable number of patients (4000) on ...

Phase N/A

0.51 miles

Learn More »

Phase 3 Alogliptin Pediatric Study

The drug being tested in this study is called alogliptin. Alogliptin is being tested to treat children 10 to 17 years of age who have type 2 diabetes mellitus (T2DM) and are experiencing inadequate glycemic control. This study will look at glycosylated hemoglobin (HbA1c) fluctuations in children who take alogliptin ...

Phase

0.88 miles

Learn More »

A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants with type 2 diabetes. The study duration is approximately 60 weeks.

Phase

0.88 miles

Learn More »

Adverse Metabolic Effects of Dietary Sugar

Recent studies have demonstrated that consuming high fructose corn syrup (HFCS)- or sucrose-sweetened beverages increased lipid/lipoprotein risk factors for cardiovascular disease (CVD) in healthy adults compared with iso-caloric amounts of glucose or low-fat milk. The longest of these studies, which utilized a 6-month intervention, also showed increased liver and muscle ...

Phase N/A

0.88 miles

Learn More »

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

The study duration as approximately 29 weeks including 2 weeks screening period, 26 weeks open label treatment period, and a 3 days follow-up period.

Phase

0.88 miles

Learn More »

Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis

Schizophrenia is a severe mental disorder that is marked by significant disruption in a person's thought and emotional processes, frequently involving psychotic features. Identifying behavioral changes and symptoms that indicate the beginning stages of schizophrenia is important for early intervention and prevention of a full psychotic episode. These initial symptoms, ...

Phase

2.44 miles

Learn More »

A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

This study will examine the safety and anticancer activity of enfortumab vedotin given intravenously to patients with locally advanced or metastatic urothelial cancer who previously received a CPI and either previously received platinum-containing chemotherapy (Cohort 1) or are platinum-nave and cisplatin-ineligible (Cohort 2). Patients who received platinum in the adjuvant/neoadjuvant ...

Phase

2.98 miles

Learn More »

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

A single-arm, open-label study to assess the overall safety of rovalpituzumab tesirine in participants with relapsed or refractory delta-like protein 3 (DLL3) expressing small cell lung cancer by evaluating the frequency of high grade (>= Grade 3) select treatment-emergent adverse events (TEAEs).

Phase

2.98 miles

Learn More »

A Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure are eligible for ...

Phase

2.98 miles

Learn More »

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

PRIMARY OBJECTIVES: I. Measure the ability of two dose levels of bupropion hydrochloride (bupropion), 150 or 300 mg of extended release, to improve sexual desire more than a placebo at 9 weeks (8 weeks on the target dose) as measured by the desire subscale of the female sexual function index ...

Phase

2.98 miles

Learn More »